Remarkably, upon conducting a subgroup analysis based on the expression of PD-L1 (using Tumor Cell Proportion Score, TPS), patients exhibiting high PD-L1 expression levels (TPS ≥50%) demonstrated notably superior benefits, further illuminating the potential of this novel treatment [20]. This evidence concerns the gene CD274 and neoplasm.